PMID- 36979900
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230331
IS  - 2227-9059 (Print)
IS  - 2227-9059 (Electronic)
IS  - 2227-9059 (Linking)
VI  - 11
IP  - 3
DP  - 2023 Mar 16
TI  - Efficacy of Serotonin and Dopamine Activity Modulators in the Treatment of 
      Negative Symptoms in Schizophrenia: A Rapid Review.
LID - 10.3390/biomedicines11030921 [doi]
LID - 921
AB  - Schizophrenia is among the fifteen most disabling diseases worldwide. Negative 
      symptoms (NS) are highly prevalent in schizophrenia, negatively affect the 
      functional outcome of the disorder, and their treatment is difficult and rarely 
      specifically investigated. Serotonin-dopamine activity modulators (SDAMs), of 
      which aripiprazole, cariprazine, brexpiprazole, and lumateperone were approved 
      for schizophrenia treatment, represent a possible therapy to reduce NS. The aim 
      of this rapid review is to summarize the evidence on this topic to make it 
      readily available for psychiatrists treating NS and for further research. We 
      searched the PubMed database for original studies using SDAM, aripiprazole, 
      cariprazine, brexpiprazole, lumateperone, schizophrenia, and NS as keywords. We 
      included four mega-analyses, eight meta-analyses, two post hoc analyses, and 20 
      clinical trials. Aripiprazole, cariprazine, and brexpiprazole were more effective 
      than placebo in reducing NS. Only six studies compared SDAMs with other classes 
      of antipsychotics, demonstrating a superiority in the treatment of NS mainly for 
      cariprazine. The lack of specific research and various methodological issues, 
      related to the study population and the assessment of NS, may have led to these 
      partial results. Here, we highlight the need to conduct new methodologically 
      robust investigations with head-to-head treatment comparisons and long-term 
      observational studies on homogeneous groups of patients evaluating persistent NS 
      with first- and second-generation scales, namely the Brief Negative Symptom Scale 
      and the Clinical Assessment Interview for Negative Symptoms. This rapid review 
      can expand research on NS therapeutic strategies in schizophrenia, which is 
      fundamental for the long-term improvement of patients' quality of life.
FAU - Brasso, Claudio
AU  - Brasso C
AUID- ORCID: 0000-0001-9363-2506
AD  - Department of Neuroscience "Rita Levi Montalcini", University of Turin, 10124 
      Torino, Italy.
FAU - Colli, Gianluca
AU  - Colli G
AD  - Department of Neuroscience "Rita Levi Montalcini", University of Turin, 10124 
      Torino, Italy.
FAU - Sgro, Rodolfo
AU  - Sgro R
AD  - Department of Neuroscience "Rita Levi Montalcini", University of Turin, 10124 
      Torino, Italy.
FAU - Bellino, Silvio
AU  - Bellino S
AUID- ORCID: 0000-0002-6555-8000
AD  - Department of Neuroscience "Rita Levi Montalcini", University of Turin, 10124 
      Torino, Italy.
FAU - Bozzatello, Paola
AU  - Bozzatello P
AD  - Department of Neuroscience "Rita Levi Montalcini", University of Turin, 10124 
      Torino, Italy.
FAU - Montemagni, Cristiana
AU  - Montemagni C
AD  - Department of Neuroscience "Rita Levi Montalcini", University of Turin, 10124 
      Torino, Italy.
FAU - Villari, Vincenzo
AU  - Villari V
AD  - Psychiatric Emergency Service, Department of Neuroscience and Mental Health, 
      Azienda Ospedaliero-Universitaria "Citta della Salute e della Scienza di Torino", 
      10126 Turin, Italy.
FAU - Rocca, Paola
AU  - Rocca P
AUID- ORCID: 0000-0002-6414-3559
AD  - Department of Neuroscience "Rita Levi Montalcini", University of Turin, 10124 
      Torino, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230316
PL  - Switzerland
TA  - Biomedicines
JT  - Biomedicines
JID - 101691304
PMC - PMC10046337
OTO - NOTNLM
OT  - SDAMs
OT  - antipsychotic
OT  - aripiprazole
OT  - brexpiprazole
OT  - cariprazine
OT  - lumateperone
OT  - negative symptoms
OT  - schizophrenia
OT  - schizophrenia spectrum disorders
OT  - serotonin-dopamine activity modulators
COIS- The authors declare no conflict of interest.
EDAT- 2023/03/30 06:00
MHDA- 2023/03/30 06:01
PMCR- 2023/03/16
CRDT- 2023/03/29 01:21
PHST- 2023/01/24 00:00 [received]
PHST- 2023/03/10 00:00 [revised]
PHST- 2023/03/13 00:00 [accepted]
PHST- 2023/03/30 06:01 [medline]
PHST- 2023/03/29 01:21 [entrez]
PHST- 2023/03/30 06:00 [pubmed]
PHST- 2023/03/16 00:00 [pmc-release]
AID - biomedicines11030921 [pii]
AID - biomedicines-11-00921 [pii]
AID - 10.3390/biomedicines11030921 [doi]
PST - epublish
SO  - Biomedicines. 2023 Mar 16;11(3):921. doi: 10.3390/biomedicines11030921.